These results suggest that Piezo1 can be used as a prognostic biomarker for glioblastoma patients in conjunction with molecular markers such as IDH wild-type, 1p/19q non-coding, and non-G-CIMP phenotypes. This evidence concerns the gene PIEZO1 and glioblastoma.